<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Sangamo Therapeutics Inc — News on 6ix</title>
    <link>https://6ix.com/company/sangamo-therapeutics-inc</link>
    <description>Latest news and press releases for Sangamo Therapeutics Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 29 Apr 2026 12:05:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/sangamo-therapeutics-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835bf6f78dffbe2df118121.webp</url>
      <title>Sangamo Therapeutics Inc</title>
      <link>https://6ix.com/company/sangamo-therapeutics-inc</link>
    </image>
    <item>
      <title>Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture Market</title>
      <link>https://6ix.com/company/sangamo-therapeutics-inc/news/sangamo-therapeutics-announces-transition-to-trading-on-otcqb-venture-market</link>
      <guid isPermaLink="true">https://6ix.com/company/sangamo-therapeutics-inc/news/sangamo-therapeutics-announces-transition-to-trading-on-otcqb-venture-market</guid>
      <pubDate>Wed, 29 Apr 2026 12:05:00 GMT</pubDate>
      <description>Sangamo’s common stock to transition trading from The Nasdaq Capital Market to OTCQB Venture Market beginning May 5, 2026RICHMOND, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that its common stock will transition from trading on The Nasdaq Capital Market to the OTCQB Venture Market on Tuesday, May 5, 2026. This transition follows the receipt by Sangamo of a notice from The Nasdaq Stock Market LLC indicating tha</description>
    </item>
    <item>
      <title>Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results</title>
      <link>https://6ix.com/company/sangamo-therapeutics-inc/news/sangamo-therapeutics-reports-recent-business-highlights-and-fourth-quarter-and-full-year-2025-financial-results</link>
      <guid isPermaLink="true">https://6ix.com/company/sangamo-therapeutics-inc/news/sangamo-therapeutics-reports-recent-business-highlights-and-fourth-quarter-and-full-year-2025-financial-results</guid>
      <pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
      <description>Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time BRISBANE, Calif.--(BUSINESS WIRE)-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic</description>
    </item>
    <item>
      <title>Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call</title>
      <link>https://6ix.com/company/sangamo-therapeutics-inc/news/sangamo-therapeutics-announces-fourth-quarter-and-full-year-2025-earnings-call</link>
      <guid isPermaLink="true">https://6ix.com/company/sangamo-therapeutics-inc/news/sangamo-therapeutics-announces-fourth-quarter-and-full-year-2025-earnings-call</guid>
      <pubDate>Thu, 19 Mar 2026 04:00:00 GMT</pubDate>
      <description>RICHMOND, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company today announced that the company</description>
    </item>
    <item>
      <title>Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease</title>
      <link>https://6ix.com/company/sangamo-therapeutics-inc/news/sangamo-therapeutics-advances-rolling-submission-of-bla-to-us-fda-for-st-920-in-fabry-disease</link>
      <guid isPermaLink="true">https://6ix.com/company/sangamo-therapeutics-inc/news/sangamo-therapeutics-advances-rolling-submission-of-bla-to-us-fda-for-st-920-in-fabry-disease</guid>
      <pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
      <description>Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ</description>
    </item>
    <item>
      <title>Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026</title>
      <link>https://6ix.com/company/sangamo-therapeutics-inc/news/sangamo-therapeutics-presents-detailed-data-210500648</link>
      <guid isPermaLink="true">https://6ix.com/company/sangamo-therapeutics-inc/news/sangamo-therapeutics-presents-detailed-data-210500648</guid>
      <pubDate>Tue, 03 Feb 2026 21:05:00 GMT</pubDate>
      <description>Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally shift Fabry treatment paradigm STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed can serve as primary basis of approval Rolling submission of</description>
    </item>
    <item>
      <title>Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering</title>
      <link>https://6ix.com/company/sangamo-therapeutics-inc/news/sangamo-therapeutics-announces-pricing-25-141000137</link>
      <guid isPermaLink="true">https://6ix.com/company/sangamo-therapeutics-inc/news/sangamo-therapeutics-announces-pricing-25-141000137</guid>
      <pubDate>Tue, 03 Feb 2026 14:10:00 GMT</pubDate>
      <description>RICHMOND, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 35,190,292 shares of its common stock and pre-funded warrants to purchase 17,787,033 shares of its common stock, together with accompanying warrants to purchase 52,977,325 shares of its common stock. The combined offering price of each share of common stock and accompanying warrant is $0.4719. The combined</description>
    </item>
    <item>
      <title>Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease</title>
      <link>https://6ix.com/company/sangamo-therapeutics-inc/news/sangamo-therapeutics-initiates-rolling-submission-bla-us-fda-st-920-fabry-disease</link>
      <guid isPermaLink="true">https://6ix.com/company/sangamo-therapeutics-inc/news/sangamo-therapeutics-initiates-rolling-submission-bla-us-fda-st-920-fabry-disease</guid>
      <pubDate>Thu, 18 Dec 2025 05:00:00 GMT</pubDate>
      <description>STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which</description>
    </item>
    <item>
      <title>Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy</title>
      <link>https://6ix.com/company/sangamo-therapeutics-inc/news/sangamo-therapeutics-receives-us-fda-fast-track-designation-st-503-treatment-small</link>
      <guid isPermaLink="true">https://6ix.com/company/sangamo-therapeutics-inc/news/sangamo-therapeutics-receives-us-fda-fast-track-designation-st-503-treatment-small</guid>
      <pubDate>Tue, 02 Dec 2025 05:00:00 GMT</pubDate>
      <description>RICHMOND, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food</description>
    </item>
    <item>
      <title>Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease</title>
      <link>https://6ix.com/company/sangamo-therapeutics-inc/news/sangamo-therapeutics-announces-fda-acceptance-bla-rolling-submission-request-st-920</link>
      <guid isPermaLink="true">https://6ix.com/company/sangamo-therapeutics-inc/news/sangamo-therapeutics-announces-fda-acceptance-bla-rolling-submission-request-st-920</guid>
      <pubDate>Fri, 21 Nov 2025 05:00:00 GMT</pubDate>
      <description>RICHMOND, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food</description>
    </item>
    <item>
      <title>Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results</title>
      <link>https://6ix.com/company/sangamo-therapeutics-inc/news/sangamo-therapeutics-reports-recent-business-highlights-and-third-quarter-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/sangamo-therapeutics-inc/news/sangamo-therapeutics-reports-recent-business-highlights-and-third-quarter-2025</guid>
      <pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
      <description>Held meeting with U.S. Food and Drug Administration (FDA) where, among other things, they reiterated October 2024 agreement to use estimated glomerular</description>
    </item>
    <item>
      <title>Sangamo Therapeutics Announces Third Quarter 2025 Earnings Call</title>
      <link>https://6ix.com/company/sangamo-therapeutics-inc/news/sangamo-therapeutics-announces-third-quarter-2025-earnings-call-2025-10-30</link>
      <guid isPermaLink="true">https://6ix.com/company/sangamo-therapeutics-inc/news/sangamo-therapeutics-announces-third-quarter-2025-earnings-call-2025-10-30</guid>
      <pubDate>Thu, 30 Oct 2025 04:00:00 GMT</pubDate>
      <description>RICHMOND, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the company</description>
    </item>
    <item>
      <title>Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025</title>
      <link>https://6ix.com/company/sangamo-therapeutics-inc/news/sangamo-therapeutics-presents-detailed-data-registrational-staar-study-fabry-disease</link>
      <guid isPermaLink="true">https://6ix.com/company/sangamo-therapeutics-inc/news/sangamo-therapeutics-presents-detailed-data-registrational-staar-study-fabry-disease</guid>
      <pubDate>Thu, 04 Sep 2025 04:00:00 GMT</pubDate>
      <description>Totality of data supports potential for isaralgagene civaparvovec as a one-time, durable treatment of the underlying pathology of Fabry disease to provide</description>
    </item>
    <item>
      <title>Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results</title>
      <link>https://6ix.com/company/sangamo-therapeutics-inc/news/sangamo-therapeutics-reports-recent-business-highlights-and-second-quarter-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/sangamo-therapeutics-inc/news/sangamo-therapeutics-reports-recent-business-highlights-and-second-quarter-2025</guid>
      <pubDate>Thu, 07 Aug 2025 04:00:00 GMT</pubDate>
      <description>Announced positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate</description>
    </item>
    <item>
      <title>Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call</title>
      <link>https://6ix.com/company/sangamo-therapeutics-inc/news/sangamo-therapeutics-announces-second-quarter-2025-earnings-call-2025-07-31</link>
      <guid isPermaLink="true">https://6ix.com/company/sangamo-therapeutics-inc/news/sangamo-therapeutics-announces-second-quarter-2025-earnings-call-2025-07-31</guid>
      <pubDate>Thu, 31 Jul 2025 04:00:00 GMT</pubDate>
      <description>RICHMOND, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company today announced that the company has</description>
    </item>
    <item>
      <title>Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease</title>
      <link>https://6ix.com/company/sangamo-therapeutics-inc/news/sangamo-therapeutics-announces-positive-topline-results-registrational-staar-study</link>
      <guid isPermaLink="true">https://6ix.com/company/sangamo-therapeutics-inc/news/sangamo-therapeutics-announces-positive-topline-results-registrational-staar-study</guid>
      <pubDate>Tue, 24 Jun 2025 04:00:00 GMT</pubDate>
      <description>STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which</description>
    </item>
    <item>
      <title>Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results</title>
      <link>https://6ix.com/company/sangamo-therapeutics-inc/news/sangamo-therapeutics-reports-recent-business-highlights-and-first-quarter-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/sangamo-therapeutics-inc/news/sangamo-therapeutics-reports-recent-business-highlights-and-first-quarter-2025</guid>
      <pubDate>Mon, 12 May 2025 04:00:00 GMT</pubDate>
      <description>Announced capsid license agreement with Lilly to deliver genomic medicines for up to five central nervous system (CNS) disease targets. Received $18 million</description>
    </item>
    <item>
      <title>Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering</title>
      <link>https://6ix.com/company/sangamo-therapeutics-inc/news/sangamo-therapeutics-announces-pricing-230-million-underwritten-offering-2025-05-12</link>
      <guid isPermaLink="true">https://6ix.com/company/sangamo-therapeutics-inc/news/sangamo-therapeutics-announces-pricing-230-million-underwritten-offering-2025-05-12</guid>
      <pubDate>Mon, 12 May 2025 04:00:00 GMT</pubDate>
      <description>RICHMOND, Calif.--(BUSINESS WIRE)-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the pricing of an underwritten</description>
    </item>
    <item>
      <title>Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day</title>
      <link>https://6ix.com/company/sangamo-therapeutics-inc/news/sangamo-therapeutics-postpones-first-quarter-2025-conference-call-later-same-day-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/sangamo-therapeutics-inc/news/sangamo-therapeutics-postpones-first-quarter-2025-conference-call-later-same-day-2025</guid>
      <pubDate>Mon, 12 May 2025 04:00:00 GMT</pubDate>
      <description>RICHMOND, Calif.--(BUSINESS WIRE)-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the first quarter earnings</description>
    </item>
    <item>
      <title>Sangamo Therapeutics Announces First Quarter 2025 Earnings Call</title>
      <link>https://6ix.com/company/sangamo-therapeutics-inc/news/sangamo-therapeutics-announces-first-quarter-2025-earnings-call-2025-05-06</link>
      <guid isPermaLink="true">https://6ix.com/company/sangamo-therapeutics-inc/news/sangamo-therapeutics-announces-first-quarter-2025-earnings-call-2025-05-06</guid>
      <pubDate>Tue, 06 May 2025 04:00:00 GMT</pubDate>
      <description>RICHMOND, Calif.--(BUSINESS WIRE)-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the company has scheduled the</description>
    </item>
    <item>
      <title>Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease</title>
      <link>https://6ix.com/company/sangamo-therapeutics-inc/news/sangamo-therapeutics-announces-important-derisking-milestones-pathway-anticipated-bla</link>
      <guid isPermaLink="true">https://6ix.com/company/sangamo-therapeutics-inc/news/sangamo-therapeutics-announces-important-derisking-milestones-pathway-anticipated-bla</guid>
      <pubDate>Tue, 06 May 2025 04:00:00 GMT</pubDate>
      <description>All dosed patients have passed one-year milestone required by U.S. Food and Drug Administration (FDA) for Accelerated Approval regulatory pathway for ST-920.</description>
    </item>
  </channel>
</rss>